Effects of Aerobic Exercise on the Cerebral Arterial System, Cognitive, and Motor Function in Post-stroke Patients.
NCT05706168, Not applicable, Unknown, The Hong Kong Polytechnic University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Aerobic Exercise on the Cerebral Arterial System, Cognitive, and Motor Function in Post-stroke Patients. | ClinicalTrials.gov |
| NCT number | NCT05706168 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The Hong Kong Polytechnic University | ClinicalTrials.gov |
| Conditions | Stroke | ClinicalTrials.gov |
| Interventions | treadmill exercise, Cycle ergometer exercise | ClinicalTrials.gov |
| First posted | 2023-01-31 | ClinicalTrials.gov |
| Last updated | 2024-02-28 | ClinicalTrials.gov |
Registered outcomes 40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in the carotid intima media thickness (CIMT) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The Carotid intima media thickness (CIMT) for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using the semi-automated arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea)at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in CIMT will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) CIMT absolute values, 2.)Percentage (%) change score= ((overall change score/ mean baseline CIMT values)\*100), and 3.)Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the Carotid arterial stiffness (CAS) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The Carotid arterial stiffness (CAS) for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using the semi-automated arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in CAS will be reported as: 1,) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) CAS Beta Stiffness Index (β) absolute values, 2.) Percentage (%) change score= (overall change score/ mean baseline CAS Beta Stiffness Index (β) values\*100), and 3.) Standardized mean difference (SMD) = (overall change score in AET group- change score in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the degree of stenosis following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The degree of stenosis for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using the 3D arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (corresponding to end of the AET program). The changes in the degree of stenosis will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) volume stenosis absolute values. 2.) Percentage (%) change score= ((overall change score/ mean baseline volume stenosis values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the plaque Gray scale median values (GSM) following a 12weeks Aerobic exercise training (AET) programme as assessed by the Adobe Photoshop software. | Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The plaque Gray scale median values for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using the Adobe Photoshop software at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (corresponding to end of the AET program). The changes in GSM values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) GSM values. 2.) Percentage (%) change score= ((overall change score/ mean baseline GSM values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cerebral arteries' Peak systolic velocity (PSV) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography (DCUS) and Transcranial Doppler (TCD) Ultrasonography. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The cerebral arteries' Peak systolic velocity for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using Spectral Doppler analysis on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in PSV values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) PSV values. 2.) Percentage (%) change score= ((overall change score/ mean baseline PSV values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cerebral arteries' End diastolic velocity (EDV) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The cerebral arteries' End diastolic velocity for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using Spectral Doppler analysis on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in EDV values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) EDV values. 3.) Percentage (%) change score= ((overall change score/ mean baseline EDV values)\*100), and 4.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cerebral arteries' mean flow velocity (MFV) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The cerebral arteries' mean flow velocity for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using Spectral Doppler analysis on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in MFV values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) MFV values, 2.) Percentage (%) change score= ((overall change score/ mean baseline MFV values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cerebral arteries' Resistivity index (RI) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The cerebral arteries' Resistivity Index for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using Spectral Doppler analysis on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in PSV values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) RI values, 2.) Percentage (%) change score= ((overall change score/ mean baseline RI values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cerebral arteries' Pulsatility index (PI) following a 12weeks Aerobic exercise training (AET) programme as assessed by duplex carotid ultrasonography. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The cerebral arteries' Pulsatility Index for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be assessed using Spectral Doppler analysis on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks corresponding to end of the AET program). The changes in PI values will be reported as: 1.) Overall Change score= mean differences (MD) between Baseline (enrolment) and end of AET programme (at 12weeks) PI values, 2.) Percentage (%) change score= ((overall change score/ mean baseline PI values)\*100), and 3.) Standardized mean difference (SMD) = (mean difference between change scores in AET group and change scores in control group) divided by the mean standard deviation of the two groups. | ClinicalTrials.gov |
| Primary | Changes in the cognitive function as assessed by Montreal Cognitive assessment Hong Kong version Tool. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The Montreal Cognitive Assessment Hong Kong version(MCAHKv) scores for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be measured at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (end of the AET program)). The differences between Baseline (enrollment) scores and end of AET at 12weeks scores will represent the overall change score in the cognitive function that may be attributed to AET. | ClinicalTrials.gov |
| Primary | Changes in the cognitive function as assessed by the Stroop word color Test (SWCT)Tool. | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The Stroop color word test (SWCT) scores for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be measured at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (end of the AET program)). The differences between Baseline (enrollment) scores and end of AET at 12weeks scores will represent the overall change score in the cognitive function that may be attributed to AET. | ClinicalTrials.gov |
| Primary | Changes in the motor function as assessed by the six minute walk test | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The 6MWT distance for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be measured at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (end of the AET program)). The differences between Baseline (enrollment) scores and end of AET at 12weeks scores will represent the overall change score in the motor function(endurance) that may be attributed to AET. | ClinicalTrials.gov |
| Primary | Changes in the motor function as assessed by the Timed up and go test(TUG). | Time Frame: Baseline(enrollment) to midpoint of AET at 6weeks and Baseline to end of AET at 12weeks | The TUG test walk time for the 3 post stroke subjects groups (control, treadmill, and cycle ergometer) will be measured at 3 time periods (Baseline, midpoint at 6weeks, and at 12 weeks (end of the AET program)). The differences between Baseline (enrollment) scores and end of AET at 12weeks scores will represent the overall change score in the motor function (speed) that may be attributed to AET. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' carotid intima media thickness (CIMT) as assessed by duplex carotid ultrasonography. | single point-Baseline | The Carotid intima media thickness (CIMT) of the post-stroke patients and age-matched non-stroke subjects will be assessed using the semi-automated arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) ultrasonography machine at one time period. The differences in CIMT between the two subject groups will be represented by1.) Absolute and 2.) Percentage (%) differences between the mean CIMT values of the two groups. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' Carotid arterial stiffness (CAS), Beta Stiffness Index (β) as assessed by duplex carotid ultrasonography. | single point-Baseline | The Carotid arterial stiffness (CAS) of the post-stroke patients and age-matched non-stroke subjects are assessed using the semi-automated arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) and compared at one time period. The differences in CAS between the two subject groups will be represented by: 1.) Absolute and 2.) Percentage (%) differences between the mean CAS beta Stiffness Index (β) values of the two groups. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' degree of volume stenosis as assessed by 3 dimensional(3D) carotid ultrasonography. | single point-Baseline | The degree of carotid artery volume stenosis of the post-stroke patients and age-matched non-stroke subjects are assessed using the 3D arterial analysis software on the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) and compared at one time period. The differences in the degree of volume stenosis between the two subject groups will be represented by the 1.) Absolute and 2.) Percentage (%) differences between the mean volume stenosis of the two groups, and 3.) Differences in proportions of participants with greater than 50% volume stenosis. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' Plaque Gray scale median (GSM) values as assessed by Adobe Photoshop software. | single point-Baseline | The duplex carotid ultrasonography images showing Plaques for both the post-stroke participants and age-matched non-stroke participants will have the plaques GSM values assessed at one time period using an Adobe Photoshop software. 1.) Absolute and 2.) Percentage differences in the Plaque GSM values between the two groups will represent the differences in the Plaque GSM values of the two groups. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' cerebral arteries Peak systolic velocity (PSV) as assessed by Duplex carotid ultrasonography (DCUS) and Transcranial Doppler (TCD) ultrasonography. | single point-Baseline | The cerebral arteries Peak systolic velocity of the post-stroke patients and age-matched non-stroke subjects will be assessed using the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) Spectral Doppler Analysis (extracranial) and TCD(intracranial). The PSV between the two groups will be compared at one time period. 1.) Absolute and 2.) Percentage (%) differences in the PSV values will represent the differences in the PSV values of the two groups. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' cerebral arteries End diastolic velocity (EDV) as assessed by Duplex carotid ultrasonography (DCUS) and transcranial Doppler (TCD) ultrasonography. | single point-Baseline | The cerebral arteries End diastolic velocity of the post-stroke patients and age-matched non-stroke subjects will be assessed using the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) Spectral Doppler Analysis (extracranial) and TCD(intracranial). The EDV between the two groups will be compared at one time period. 1.) Absolute and 2.) Percentage (%) differences in the EDV values will represent the differences in the EDV of the two groups. | ClinicalTrials.gov |
| Primary | Differences between the post-stroke patients and age-matched non-stroke subjects' cerebral arteries Mean flow velocity (MFV) as assessed by Duplex carotid ultrasonography (DCUS) and transcranial Doppler (TCD) ultrasonography. | single point-Baseline | The cerebral arteries Mean flow velocity of the post-stroke patients and age-matched non-stroke subjects are assessed using the Samsung RS80A ultrasound machine (Samsung Medison Co., Ltd., Republic of Korea) Spectral Doppler Analysis (extracranial) and TCD(intracranial). The MFV between the two groups will be compared at one time period. 1.) Absolute and 2.) Percentage (%) differences in the MFV values will represent the differences in the MFV of the two groups. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 21
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 14599231 | BACKGROUND | PubMed |
| 21044719 | BACKGROUND | PubMed |
| 21636819 | BACKGROUND | PubMed |
| 23111686 | BACKGROUND | PubMed |
| 23361485 | BACKGROUND | PubMed |
| 23428993 | BACKGROUND | PubMed |
| 24455270 | BACKGROUND | PubMed |
| 27531500 | BACKGROUND | PubMed |
| 27720278 | BACKGROUND | PubMed |
| 28084167 | BACKGROUND | PubMed |
| 30571438 | BACKGROUND | PubMed |
| 30760772 | BACKGROUND | PubMed |
| 32600741 | BACKGROUND | PubMed |
| 32826385 | BACKGROUND | PubMed |
| 34069792 | BACKGROUND | PubMed |
| 34079702 | BACKGROUND | PubMed |
| 34306452 | BACKGROUND | PubMed |
| 34340643 | BACKGROUND | PubMed |
| 34487721 | BACKGROUND | PubMed |
| 36229774 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)